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Neurobiology of Disease
Convergence of Hippocampal Pathophysiology in Syngap/
and Fmr1/y Mice
XStephanie A. Barnes,1 Lasani S. Wijetunge,1,2 XAdamD. Jackson,1,3* Danai Katsanevaki,1* Emily K. Osterweil,1,4*
Noboru H. Komiyama,5 XSeth G.N. Grant,5 XMark F. Bear,4U. Valentin Na¨gerl,2 Peter C. Kind,1,3†
and XDavid J.A. Wyllie1,3†
1Centre for Integrative Physiology and Patrick Wild Centre, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom, 2Interdisciplinary Institute for
Neuroscience, Centre National de la Recherche Scientifique, Unite´ Mixte de Recherche 5297, University of Bordeaux, Bordeaux 33077, France, 3Centre for
Brain Development and Repair, inStem, Bangalore 560065, India, 4Picower Institute for Learning and Memory, Massachusetts Institute of Technology,
Cambridge, Massachusetts 02139, and 5Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, United Kingdom
Previous studies have hypothesized that diverse genetic causes of intellectual disability (ID) and autism spectrum disorders (ASDs)
converge on common cellular pathways. Testing this hypothesis requires detailed phenotypic analyses of animal models with genetic
mutations that accurately reflect those seen in the human condition (i.e., have structural validity) and which produce phenotypes
that mirror ID/ASDs (i.e., have face validity). We show that SynGAP haploinsufficiency, which causes ID with co-occurring ASD in
humans, mimics and occludes the synaptic pathophysiology associated with deletion of the Fmr1 gene. Syngap/ and Fmr1/y mice
show increases in basal protein synthesis andmetabotropic glutamate receptor (mGluR)-dependent long-termdepression that, unlike in
their wild-type controls, is independent of new protein synthesis. Basal levels of phosphorylated ERK1/2 are also elevated in Syngap/
hippocampal slices. Super-resolution microscopy reveals that Syngap/ and Fmr1/y mice show nanoscale alterations in dendritic
spinemorphology that predict an increase in biochemical compartmentalization. Finally, increased basal protein synthesis is rescued by
negative regulators of the mGlu subtype 5 receptor and the Ras–ERK1/2 pathway, indicating that therapeutic interventions for fragile X
syndromemay benefit patients with SYNGAP1 haploinsufficiency.
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Introduction
Intellectual disability (ID) refers to a group of neurodevelopmen-
tal disorders characterized by an intelligence quotient (IQ) below
70, which affects 2–3% of the population (Huang, 2009).
Large-scale genetic studies have shown that the genetic causes of
ID are highly heterogeneous involving chromosomal abnormal-
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Significance Statement
As the genetics of intellectual disability (ID) and autism spectrum disorders (ASDs) are unraveled, a key issue is whether geneti-
cally divergent forms of these disorders converge on common biochemical/cellular pathways and hence may be amenable to
common therapeutic interventions. This study compares the pathophysiology associated with the loss of fragile X mental retar-
dation protein (FMRP) and haploinsufficiency of synaptic GTPase-activating protein (SynGAP), two prevalent monogenic forms
of ID.We show that Syngap/mice phenocopyFmr1/ymice in the alterations inmGluR-dependent long-termdepression, basal
protein synthesis, and dendritic spine morphology. Deficits in basal protein synthesis can be rescued by pharmacological inter-
ventions that reduce the mGlu5 receptor–ERK1/2 signaling pathway, which also rescues the same deficit in Fmr1
/y mice. Our
findings support the hypothesis that phenotypes associated with genetically diverse forms of ID/ASDs result from alterations in
common cellular/biochemical pathways.
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ities and single gene mutations, with several hundred ID-related
genes identified (Krumm et al., 2014). Estimates of comorbidity
indicate that 30% of people with ID also present with autism
spectrum disorders (ASDs), suggesting significant genetic over-
lap between these two disorders. For example, one-third of all
boys with fragile X syndrome (FXS) also meet the diagnostic
criteria for autism (Wijetunge et al., 2013).
Although the genetic causes of ID/ASDs are highly diverse,
previous studies suggest that there may be convergence at the
level of biochemical pathways that are affected. For example, FXS
and tuberous sclerosis complex (TSC), two monogenic causes of
ID with overlapping clinical symptoms, appear to be on opposite
ends of a common pathophysiological axis (Auerbach et al.,
2011). Thus, it is possible that rare but highly penetrant genetic
mutations (e.g., FXS and TSC) may give insight into the patho-
physiology of a range of IDs/ASDs (Wijetunge et al., 2013).
A core physiological consequence of the loss of fragile Xmen-
tal retardation protein (FMRP) is an increase in basal protein
synthesis downstream of mGlu5 receptor activation (Qin et al.,
2005; Do¨len et al., 2007; Osterweil et al., 2010; Till et al., 2015). In
the hippocampus, this change can be detected as an increase in
metabotropic glutamate receptor (mGluR)-dependent long-
term synaptic depression (LTD) that, unlike in wild type (WT),
no longer requires new protein synthesis (Huber et al., 2002;
Nosyreva andHuber, 2006). ReducingmGlu5 receptor signaling,
either genetically or with negative allostericmodulators ofmGlu5
receptors, rescues many of the phenotypes associated with the
genetic deletion of FMRP (Do¨len et al., 2007; Michalon et al.,
2012; Michalon et al., 2014). In the absence of FMRP, the eleva-
tion in basal protein synthesis results from a hypersensitivity to
ERK1/2-MAPK signaling, and inhibitors of this pathway also re-
verse cellular and behavioral effects resulting from the loss of
FMRP (Osterweil et al., 2010, 2013).
In this study, we examine the pathophysiology in mice
heterozygous for a null mutation in Syngap. Synaptic GTPase-
activating protein (SynGAP) is a RasGAP encoded by a gene that
gives rise to multiple isoforms, several of which have opposing
effects on synaptic efficacy (McMahon et al., 2012). It is expressed
throughout development with the highest levels observed in the
forebrain at the peak of synaptogenesis (Porter et al., 2005; Bar-
nett et al., 2006). In human patients, de novo SYNGAP1 muta-
tions that result in a null allele lead to autosomal dominant
nonsyndromic ID (NSID) and, in a minority of cases, ASDs
(Hamdan et al., 2009, 2011; Berryer et al., 2013). Syngap
heterozygous (Syngap/) mice also show a range of behavioral,
physiological, and anatomical abnormalities throughout devel-
opment (Komiyama et al., 2002; Vazquez et al., 2004; Barnett et
al., 2006; Harlow et al., 2010; Clement et al., 2012, 2013). Fmr1/y
mice show a hypersensitivity to Ras–ERK1/2 signaling (Osterweil
et al., 2010), whereas Syngap/ mice show elevated ERK1/2
phosphorylation in the hippocampus (Komiyama et al., 2002;
Ozkan et al., 2014). The involvement of the ERK1/2 pathway led
us to hypothesize that these two genetic mutations, which cause
human ID, may share a common hippocampal pathophysiology
downstream of mGluR-dependent ERK1/2 activation.
Materials andMethods
Animals. Syngap/mutant mice, originally generated by Komiyama et
al. (2002), and Fmr1/y mice were bred on a C57Black6JOla line (Har-
lan). For genetic occlusion experiments, Syngap/ males were paired
with Fmr1/ females to obtain F1 male progeny with the following
genotypes: WT (Syngap//Fmr1/y), Fmr1 KO (Syngap//Fmr1/y),
Syngap heterozygous (Syngap//Fmr1/y), and double mutants (Syn-
gap//Fmr1/y). All experiments were performed with WT littermates
acting as controls and with the experimenter blind to genotype. All ani-
mal work was performed in accordance with the United Kingdom Ani-
mals (Scientific Procedures) Act of 1986 under the authority of Project
Licenses PPL 60/3631 and PPL 60/4290.
Hippocampal slice electrophysiology. Horizontal hippocampal slices
(400 m) were prepared from postnatal day 25–32 (P25–32) animals.
Slices were collected in carbogenated (95% oxygen, 5% CO2) ice-cold
dissection buffer containing the following (in mM): 86 NaCl, 1.2
NaH2PO4, 25 KCl, 25 NaHCO3, 20 glucose, 75 sucrose, 0.5 CaCl2, and 7
MgCl2. Slices were incubated for 30 min at 30°C in artificial CSF
(ACSF) containing the following (in mM): 124 NaCl, 1.2 NaH2PO4, 25
KCl, 25 NaHCO3, 20 glucose, 2 CaCl2, and 1 MgCl2, bubbled with
95% oxygen and 5% CO2. An incision was made through CA1–CA3
boundary, and sliceswere left to recover for aminimumof 1 h at room te-
mperature (2022°C) before any recordings were made. For electro-
physiological recordings, slices were placed in a submersion chamber
heated to 30°C and perfused with carbogenated ACSF containing picro-
toxin (50 M) at a rate of 4 ml/min.
Field EPSPs (fEPSPs) were recorded at Schaffer collateral/commis-
sural inputs to CA1 pyramidal neurons using extracellular recording
electrodes (1–3 M) filled with ACSF and placed in the stratum radia-
tum layer of the CA1 area. Synaptic responses were evoked by applying
single current pulses to the Schaffer collateral/commissural axons using a
bipolar stimulating electrode. Stimuli (10–30 A, 200 s, delivered at a
frequency of 0.033 Hz) were set to produce 30–60% of the maximal
response amplitude.
Metabotropic glutamate receptor-dependent LTD (mGluR-LTD) was
induced by acute application (5 min) of the group 1 mGluR agonist
(R,S)-3,5-dihydroxyphenylglycine (DHPG; 50M) in the presence of the
NMDAR antagonist D-AP5 (50 M). For experiments involving aniso-
mycin, slices were preincubated for 30min in ACSF containing anisomy-
cin (20 M) before LTD induction, which remained present for the
duration of the recording.
Electrophysiological traces were collected using WinLTP (University
of Bristol, Bristol, UK) and exported to Microsoft Excel. The magnitude
of LTD was calculated by dividing the average fEPSP slope from 40 to 60
min after DHPG application by the average fEPSP slope during the 20
min baseline before DHPG application. Statistical analysis was per-
formed using GraphPad Prism routines (GraphPad Software). After
genotyping, time-matched normalized data were averaged across exper-
iments and expressed as means SE. Significant differences between the
WT andmutant mice were determined using Student’s t test or ANOVA
with p 0.05.
Metabolic labeling. Protein synthesis levels were measured following
the protocol outlined by Osterweil et al. (2010). Briefly, 500 m
transverse hippocampal slices were prepared from either Syngap/
or Fmr1/y mice with WT littermates serving as interleaved controls.
Dorsal hippocampal slices were left to recover for 4 h at 30°C in
preoxygenated ACSF containing the following (in mM): 124 NaCl,
1.25 NaH2PO4, 3 KCl, 26 NaHCO3, 10 glucose, 2 CaCl2, 1 MgCl2.
Slices were transferred to a chamber containing actinomycin D (25 M) and
vehicle, 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-
imidazol-4-yl)ethynyl)pyridine (CTEP; 10 M), 1,4-diamino-2,3-
dicyano-1,4-bis (2-aminophenylthio)butadiene (U0126; 5 M), or lova-
statin (100 M) for 30 min, and then transferred to a chamber with fresh
ACSF containing 0.4 Mbq/ml 35S–Met/Cys protein labeling mix
(PerkinElmer) and vehicle, CTEP (10 M), U0126 (5 M), or lovastatin
(100 M) for 45 min. After labeling, slices were frozen on dry ice and
stored at 80°C. For processing, slices were homogenized in ice-cold
homogenising buffer (10 mMHEPES, pH 7.4, 2 mM EDTA, 2 mM EGTA,
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1% Triton X-100) with protease inhibitors (Roche) and phosphatase
inhibitors (cocktails II and III; Sigma). Protein was precipitated with
TCA (12.5% final), and total protein concentration was measured using
a Bio-Rad protein assay. Samples were read using a scintillation counter,
and data were expressed as the number of counts per minute per micro-
gram of protein and normalized to the 35S–Met/Cys ACSF used for
incubation.
Western blotting. For Western blotting, metabolically labeled hip-
pocampal homogenates were taken before TCA precipitation and boiled
in Laemmli sample buffer, resolved on SDS polyacrylamide gels (Bio-
Rad), transferred to nitrocellulose, and incubated overnight in primary
antibodies for p-ERK1/2 (Thr202/Tyr204; Cell Signaling Technology),
ERK1/2 (Cell Signaling Technology), and -actin (Abcam). Blots were
incubated with their respective fluorophore-conjugated secondary anti-
bodies and imaged on an Odyssey imaging system (LiCor Biosciences).
Stimulated emission depletion microscopy and dendritic spine analysis.
Quantitativemorphometric analysis of dendritic spines using stimulated
emission depletion (STED) microscopy on dorsal hippocampal brain
sections from perfusion-fixed P35 animals was performed as reported
previously (Wijetunge et al., 2014). Spines on three to four apical oblique
dendritic segments within stratum radiatum of CA1 were acquired per
animal where each dendrite was from a different cell and analyzed blind
to the genotype. Confocal microscopy analysis was performed as re-
ported previously (Till et al., 2012), except that the cells were filled in
lightly postfixed (4% paraformaldehyde) acute hippocampal slices from
P26–P32 animals. Statistical analyses of spine morphology were per-
formed as described previously (Wijetunge et al., 2014).
Results
Enhanced and protein synthesis independent mGluR-LTD in
Syngap/ hippocampal slices
To determine whether SynGAP haploinsufficiency results in a
hippocampal pathophysiology similar to that observed in mouse
models of FXS, we first examinedwhether the loss of a single copy
of Syngap mimics the increase in mGluR-LTD reported in
Fmr1/y mice. The application of DHPG, a selective group 1
mGluR agonist, resulted in a significant increase in the magni-
tude of LTD in Syngap/ hippocampal slices compared to WT
controls (WT, 77  3%, n  18; Syngap/, 62  5%, n  15;
p  0.012). At this developmental time point (P25–P32), the
expression of this form of LTD is dependent on the translation of
mRNAs at local dendritic sites (Huber et al., 2000). Preincuba-
tion of hippocampal slices in the protein synthesis inhibitor ani-
somycin (20 M) revealed that mGluR-LTD is no longer
dependent on new protein synthesis in Syngap/mutants (64
4%, n  14; Fig. 1B). In contrast, anisomycin eliminated the
persistent decrease in fEPSP slope following DHPG application
inWT controls (91 4%, n 12). Furthermore, consistent with
previous observations, and under our own experimental condi-
tions, we also observed exaggerated mGluR-LTD that was inde-
pendent of protein synthesis in Fmr1/y mice (Fig. 1C,D; Huber
et al., 2002; Nosyreva and Huber, 2006). Thus, these two ID-
related mutations in Fmr1 and Syngap lead to similar alterations
in protein synthesis-dependent mGluR-LTD in hippocampal
CA1.
Based on these LTD findings, we next wanted to examine
whether mutations that cause FXS and SynGAP haploinsuffi-
ciency lead to the disruption of a common pathophysiological
mechanism downstream of the mGlu5 receptor. To test this hy-
pothesis, we assessed whether introducing the Syngap mutation
into the Fmr1/y mouse would occlude or exacerbate the LTD
phenotype caused by the loss of FMRP. Figure 1, E and F, shows
that in doublemutant (Syngap//Fmr1/y)mice, themagnitude
of mGluR-LTD is not significantly greater than that observed in
either single mutant alone.
To confirm that the occlusion of LTD in the double mutants
did not arise from a “floor effect,”mGluR-LTDwas induced for a
second time 1 h after the initial stimulation to determine whether
the first application of DHPG led to a saturating level of LTD. In
agreement with previous studies (Palmer et al., 1997; Schnabel et
al., 1999; Huber et al., 2001), a subsequent application of DHPG
(50 M) significantly increased the magnitude of LTD relative to
the first stimulation in slices prepared from all four genotypes
(p 0.05; Fig. 2A,B).
Syngap/ hippocampal slices have elevated basal protein
synthesis and enhanced ERK1/2 activity
Previously, it was reported that exaggerated mGluR-LTD in
Fmr1/ymutants correlates with an increase in basal protein syn-
thesis (Do¨len et al., 2007). Therefore, we next examined protein
synthesis rates in hippocampal slices from Syngap/ mice em-
Figure 1. Syngap/ phenocopies the hippocampal synaptic pathophysiology observed in
Fmr1/y mice. A, application of DHPG (50M) induced LTD that was significantly increased in
Syngap/mice (62 5%,n 15; t test, p 0.01) versusWT littermate controls (77 3%,
n 18). Representative average fEPSPs before and after DHPG application are illustrated.B, In
the presence of protein synthesis inhibitor anisomycin (aniso.; 20M), DHPG-induced LTDwas
not sustained in WT mice (91 4%, n 12), while remaining intact in Syngap/ mice
(64 4%, n 14). C, DHPG-induced mGluR-LTD was also significantly enhanced in Fmr1/y
mice (63 4%, n 17; t test, p 0.04) versusWT littermate controls (77 5%, n 17).D,
In the presence of anisomycin, mGluR-LTD remained at a similar magnitude in the Fmr1/y
(65 7%, n 9), whereas LTD could not be sustained in WTmice (91 6%, n 8). E, The
magnitude of LTDwas significantly enhanced in the Syngap//Fmr1/y doublemutantmice
(59 4%, n 12; ANOVA, p 0.02) relative toWT littermate controls (78 3%; n 9). No
significant differences were observed in LTD magnitude between the Syngap//Fmr1/y
doublemutantmice andeither Syngap/ (604%,n10) or Fmr1/y (625%,n10;
data not illustrated) single mutant mice. F, Summary of DHPG-induced LTD for each of the four
genotypes generated from the Syngap/	 Fmr1/y cross. Box plots illustrate minima and
maxima (whiskers), median (line), mean (square symbol), and interquartile range (box). Cali-
brations:A,D, 250V, 10ms;B,C, 500V, 10ms;E, 350V, 10ms. n.s., Not significant. *p
0.05.
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ploying a similar methodology to that described previously in
Fmr1/ymutants (Fig. 3A; Osterweil et al. 2010). Consistent with
our electrophysiological findings, we found a significant increase
in 35S-Met/Cys incorporation in Syngap/ hippocampal slices
(140 12%, n 9; Fig. 3B), indicating that SynGAP may func-
tion to suppress mRNA translation under steady-state condi-
tions. Although the magnitude of this increase in basal protein
synthesis was greater than that observed in Fmr1/y versus WT
slices (121  7%; n  7), our findings suggest that the proteins
required for mGluR-LTD may be overtranslated in both the
Fmr1/ and Syngap/ brain.
In Fmr1/y mice, increased protein synthesis rates are caused
by a hypersensitive response to constitutive mGlu5–Ras–ERK1/2
signaling due the loss of the translational repression by FMRP
(Osterweil et al., 2010). In the Syngap/ hippocampus, both Ras
and ERK1/2 activity are increased (Komiyama et al., 2002; Ozkan
et al., 2014), leading us to hypothesize that elevated protein syn-
thesis rates may arise from dysregulated ERK1/2 signaling due to
the loss of Ras inactivation. To confirm that we observed a similar
increase in ERK1/2 activity, phosphorylation levels were quanti-
fied in hippocampal slices from Syngap/mice andWTcontrols
under identical conditions to which basal protein synthesis
rates were found to be enhanced. In agreement with previous
studies, ERK1/2 phosphorylation was significantly increased in
Syngap/mutants under steady-state conditions in the absence
of any detectable differences in total ERK1/2 protein (137 7%,
n 23; p 1.5	 105; Fig. 3C).
It was shown previously that an mGluR-LTD-inducing stim-
ulus increases protein synthesis rates in WT but not Fmr1/y
hippocampal slices (Osterweil et al., 2010). Thus, we measured
35S-Met/Cys incorporation following the acute application of
DHPG (100 M; 5 min) in Syngap/ hippocampal slices. While
DHPG stimulation significantly enhanced protein synthesis in
WT slices, the same treatment failed to increase further the al-
ready exacerbated protein synthesis levels in Syngap/mutants
(Fig. 3D), suggesting that mRNA translation downstream of
group 1mGluR activation is saturated under nonstimulated con-
ditions. ERK1/2 activation is a critical step in group 1 mGluR-
mediated protein synthesis governing the expression and
maintenance of mGluR-LTD (Gallagher et al., 2004; Osterweil et
al., 2010). In bothWT and Syngap/ hippocampal slices, DHPG
induced a significant and robust increase in ERK1/2 phosphory-
lation (Fig. 3E). This result may suggest that exaggeratedmGluR-
LTD in Syngap/ hippocampal slices could arise from the
dysregulation of basal, rather than stimulated, ERK1/2 signaling.
Elevated basal protein synthesis in the Syngap/hippocampus
can be ameliorated by negativemodulators ofmGlu5 receptor
andRas–ERK1/2 signaling
To test the hypothesis that excessive mGluR-mediated protein
synthesis in Syngap/mice is a consequence of hyperactive Ras–
ERK1/2 signaling, we examined the effects of inhibitors of this
pathway on translational rates. CTEP, lovastatin, and U0126 se-
lectively target and downregulate mGlu5 receptors, Ras, and
ERK1/2 signaling, respectively (Fig. 4A), and have been shown
previously to restore exaggerated levels of protein synthesis
and/or functional deficits in Fmr1/ymice (Osterweil et al., 2010,
2013; Michalon et al., 2012, 2014). We found that each of these
compounds reduced basal protein synthesis in Syngap/ hip-
pocampal slices to levels not significantly different fromWT con-
trols (Fig. 4B,Ci,Di). Importantly, none of these compounds
significantly altered basal protein synthesis in WT animals, sug-
gesting that their effect is specific to mechanisms underlying the
hyperactivation of ERK1/2 in Syngap/ mice. To confirm that
both lovastatin and U0126 elicited their effects on protein syn-
thesis by downregulating ERK1/2 activity, we quantified the
phosphorylation status of ERK1/2 in control and treated hip-
pocampal slices from Syngap/ andWTmice. Lovastatin signif-
icantly reduced ERK1/2 phosphorylation in Syngap/ slices to
WT levels without affecting ERK1/2 phosphorylation in WT
treated slices (Fig. 4Cii,Ciii). In contrast, U0126 caused a dra-
matic reduction in ERK1/2 activity in both WT and Syngap/
hippocampal slices (Fig. 4Dii,Diii). Together, these findings
suggest that dysregulated ERK1/2 signaling leads to exaggerated
protein synthesis rates in Syngap/ hippocampus, and drugs
that have been shown previously to ameliorate phenotypes asso-
ciated with the loss of FMRP can restore translational rates in a
mouse model of SYNGAP haploinsufficiency.
Altered morphology of dendritic spines of CA1 pyramidal
neurons in Syngap/mice
Next, we examined whether the electrophysiological and bio-
chemical changes we observed in Syngap/mice are associated
with density and morphological alterations in dendritic spines,
which are the main site of excitatory input to CA1 pyramidal
neurons. To determinewhether the reduction in SynGAP expres-
sion affected the density of dendritic spines, we dye filled cells
obtained from the “partner” hemispheres of brains that had been
used for electrophysiological studies. Figure 5 illustrates that no
difference in spine densities were observed in Syngap/ mice
Figure 2. A single application of DHPG does not “saturate” LTD in Syngap//Fmr1/y
double mutant mice. A, Mean time courses illustrating fEPSP slope in experiments on slices
prepared from WT, Syngap/, and Syngap//Fmr1/y mice where two applications of
DHPG (50M) were applied to determine whether the magnitude of LTD elicited by the first
application could be augmented by the second. B, Bar graphs illustrating the magnitude of
mGluR-mediated LTD produced by a first and then a second application of DHPG in slices pre-
pared fromWT (first, 81 3%; second, 71 5%; n 8; p 0.05, paired t test), Syngap/
(first, 68 7%; second, 51 9%; n 5; p 0.05), Fmr1/y (first, 73 4%; second, 61
5%; n 3; p 0.001), and Syngap//Fmr1/y (first, 69 11%; second, 56 8%; n 4;
p 0.05) mice. *p 0.05; ***p 0.001.
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and WT littermate controls (WT, 19.58  1.03 spines/10 m;
Syngap/, 17.34  0.94 spines/10 m; p  0.1430, two-tailed
independent t test with Welch’s correction).
To accurately resolve the fine details of spine morphology we
used STED microscopy, quantifying the widths and lengths of
spine heads and necks at the nanoscale (Fig. 6A). For spine head
width, no difference in the distributions between Syngap/ and
WT neurons was observed, although spine neck lengths and
widths showed significantly different distributions (Fig. 6B–D;
WT, n 393 spines; Syngap/, n 424 spines; head width, p
0.11; neck length, p 0.005; neck width, p 0.0008, Kolmogo-
rov–Smirnov test). In agreement with our STED analysis, confo-
cal analysis of dendritic spines in the animals from which
electrophysiological analyses were performed (P25–P32) also in-
dicates that there was no difference in themean spine head width
between genotypes (WT, 0.350 0.01 m; Syngap/, 0.360
0.01 m; p  0.71, t test with Welch’s correction; data not
shown).
To better understand the potential functional impact of these
nanoscalemorphological alterations on synapse function, we cal-
culated the compartmentalization factor (defined asVL/A, where
V is the head volume, L is the neck length, and A is the cross-
sectional area of the spine neck), which serves as a measure of
the degree of biochemical compartmentalization of spine syn-
apses (Tønnesen et al., 2014). We found that the compartmen-
talization factorwas substantially increased in Syngap/ animals
(Fig. 6E; Syngap/, n 424 spines; WT, n 393 spines; com-
partmentalization factor, p 0.0001, Kolmogorov–Smirnov test;
mean compartmentalization factor,WT, 3.16 0.30m2, n 4
animals; Syngap/, 4.35 0.37 m2, n 6 animals; p 0.04,
two-tailed independent t test with Welch’s correction), indi-
cating that SynGAP expression influences the biochemical
coupling of spines to their parent dendrites. Interestingly, in
Fmr1/y mice, the compartmentalization factor was also pre-
viously found to be increased relative to WT control animals
(Wijetunge et al., 2014).
Discussion
De novo mutations in the SYNGAP1 gene result in moderate to
severe ID, often with co-occurring epilepsy and/or ASDs that
appear to be as prevalent as FXS (Berryer et al., 2013). However,
unlike FXS, little is known about the underlying mechanisms by
which SynGAP reduction causes these alterations in brain func-
tion. We now show that SynGAP haploinsufficiency in mice
mimics and/or occludes the deficits in synaptic structure and
physiology in hippocampal CA1 pyramidal neurons associated
with the loss of FMRP. Furthermore, pharmacological interven-
tions that reduce mGlu5 receptor signaling and rescue much of
the pathophysiology associated with the loss of FMRP also res-
cue the protein synthesis deficits associated with loss of a single
copy of Syngap. Together, these data suggest that these two prev-
alent monogenic causes of ID/ASDs share common and/or over-
lapping cellular mechanisms.
This is the first demonstration that Syngap/ mice show al-
tered mGlu5 receptor signaling and altered downstream protein
synthesis.When considered in conjunction with previous studies
that showed an increase in ERK1/2 activation following NMDA
receptor activation (Vazquez et al., 2004; Rumbaugh et al., 2006),
a decrease in NMDA receptor-dependent in LTP (Komiyama et
al., 2002; Kim et al., 2003), and a block of the induction ofNMDA
receptor-dependent LTD (Carlisle et al., 2008), these data suggest
that SynGAP regulates two distinct glutamate receptor depen-
Figure3. Basal protein synthesis and phosphorylated ERK1/2 levels are elevated in the hippocampus of Syngap/mice.A, Schematic of the experimental timeline for 35[S]-Met/Cysmetabolic
labeling. B, Basal protein synthesis levels were significantly elevated in dorsal hippocampal slices from Syngap/ versus WTmice (WT, 100 3%; Syngap/, 140 12%; t test, p 0.0007;
n 9). Increased protein synthesis rates were also observed in the Fmr1/y versusWTmice (WT, 100 2%; Fmr1/y, 121 7%; t test, p 0.01; n 6). Ci, Cii, Basal activation state of ERK1/2
in hippocampal slices was significantly increased in Syngap/mice versus WT controls (phosphorylated/total ERK1/2, 137 7%; n 23; p 1.5	 105). D, Protein synthesis levels were
significantly elevated in vehicle-treated dorsal hippocampal slices from Syngap/ versus WTmice (WT, 100 5%; Syngap/, 135 7%; n 6; ANOVA, p 0.0038). DHPG treatment (100
M, 5 min) significantly increased protein synthesis rates in WT slices, but did not further increase 35[S]-Met/Cys incorporation in Syngap/ slices (WT DHPG, 138 14%; Syngap/ DHPG,
148 15%; ANOVA,WT treatment, p 0.0028; n 6). Ei, Eii,Western blot analysis of vehicle/DHPG-treated hippocampal slices revealed DHPG significantly increases the phosphorylation status
of ERK1/2 in both Syngap/ and WT mice (phosphorylated/total ERK1/2, WT vehicle, 100%; Syngap/ vehicle, 130 6%; WT DHPG, 180 16%; Syngap/ DHPG, 173 21%; n 7;
ANOVA, genotype	 treatment, p 0.05). *p 0.05; **p 0.01; ***p 0.001.
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dent forms of synaptic plasticity. Intriguingly, we showed previ-
ously that the Syngap gene gives rise to a range of isoforms that are
differentially regulated by synaptic activity and that have opposing
effects on synaptic function (McMahon et al., 2012). For example,
overexpression of SynGAP A1 results in a decrease in mEPSC fre-
quency and amplitude, whereas SynGAPC2 increasesmEPSC fre-
quency and amplitude. SynGAP isoforms also demonstrate distinct
activity- andage-dependentpatternsof expression (McMahonet al.,
2012).Therefore, the lossof a single functional allele of SynGAPmay
result in an imbalance of SynGAP isoforms as well as decreasing
overall SynGAP levels. It remains to be determinedwhether the def-
icits seen in Syngap/ mice result from a reduction in total
SynGAP levels or whether an imbalance of SynGAP isoform
expression is responsible for the altered cellular phenotypes
associated with SynGAP haploinsufficiency.
Figure4. Elevatedproteinsynthesis inSyngap/hippocampusiscorrectedbyinhibitorsofmGluR5andRas–ERK1/2signaling.A, schematicofthedrugtargetsforCTEP, lovastatin,andU0126,eachshown
previously to reduceRas–ERK1/2activationandcorrectbasalprotein synthesis inFmr1/ymice.B, CTEP (10M) reverseselevatedprotein synthesis inSyngap/mice (WT, vehicle, 1003%;CTEP,106
5%;Syngap/, vehicle, 1245%;CTEP,1028%;n9;ANOVA,genotype,p0.0007;KO treatment,p0.0014).Ci–Ciii, Lovastatin (100M) reverseselevatedprotein synthesis (Ci) inSyngap/
mice (WT, vehicle, 100 4%; lovastatin, 93 7; Syngap/, vehicle, 142 9%; lovastatin, 106 8%; n 7; ANOVA, genotype, p 0.0061; KO treatment, p 0.013). ExampleWestern blot (Cii) and
quantificationofERK1/2activity (Ciii) invehicle-and lovastatin-treatedhippocampal slices revealed lovastatin significantly reducesphosphorylation levelsof ERK1/2 inSyngap/mice (phosphorylated/total
ERK1/2,WT, vehicle, 100%; Syngap/, vehicle, 1406%;WT, lovastatin, 1008%; Syngap/, lovastatin, 10611%;n10; ANOVA, genotype, *p0.0086; KO treatment,p0.0057). Thegray
line to the left of the lovastatin-treated Syngap/Westernblot indicates that this lanewasnot adjacent to eachof theother three lanes, butwas runon the samegel, andhencewasprocessed identically.D,
U0126(5M)reverseselevatedproteinsynthesis (Di) inSyngap/mice(WT,vehicle,1004%;U0126,988%;Syngap/,vehicle,1349%;U0126,1029%;n9;ANOVA,genotype,p0.003;
KO treatment, p 0.004). Example Western blot (Dii) and quantification (Diii) of ERK1/2 activity in vehicle- and U0126-treated hippocampal slices show U0126 abolishes ERK1/2 activity in both WT and
Syngap/mice(phosphorylated/totalERK1/2,WT,vehicle,100%;Syngap/, vehicle,16515%;WT, lovastatin,103%;Syngap/, lovastatin,133%;n5;ANOVA,genotype,p0.0054;WT
treatment, p 0.005; KO treatment, p 0.0002). *p 0.05; **p 0.01; ***p 0.001.
Figure 5. CA1pyramidalneurondendritic spinedensity inSyngap/mice.A, Composite imageofa
representativeCA1pyramidalneuron labeledby intracellular fillingwithAlexaFluor568 in lightly fixedsec-
tionthroughCA1ofhippocampus.Scalebar,50m.B,Representativecomposite imagesofapicaloblique
dendritic segments fromWTandSyngap/mice.Scalebars,1m.C,Meanspinedensityofapicalden-
drites forWT (n5) and Syngap/ (n6) animals indicatingnodifference indendritic spinedensity
(WT, 19.58 1.03 spines/10m; Syngap/, 17.34 0.94 spines/10m; p 0.1430, two-tailed
independent ttestwithWelch’scorrection).n.s.,Notsignificant.
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Our findings are in good agreement with a previous report
using acute and selective knockdown of the SynGAP 1 iso-
form in cortical cultures showing an ERK1/2-dependent in-
crease in dendritic protein synthesis (Wang et al., 2013). Our
data extend these findings by demonstrating that constitutive
reduction of all SynGAP isoforms, a model that more closely
reflects SYNGAP1 haploinsufficiency in humans (i.e., has ex-
cellent structural and face validity with the human condition),
leads to an increase in ERK1/2 phosphorylation and basal pro-
tein synthesis. Furthermore, the latter can be corrected by
inhibitors of the ERK1/2 signaling pathway. Importantly an
inhibitor of ERK1/2 activator MEK1/2 (U0126) restored pro-
tein synthesis to wild-type levels, despite a dramatic reduction
in ERK1/2 phosphorylation, indicating that only the exagger-
ated protein synthesis is regulated by
ERK1/2. However, it seems likely that
the dramatic reduction in ERK1/2 sig-
naling could dramatically alter neuronal
function and plasticity. In this respect,
the finding that lovastatin restored WT
levels of ERK1/2 phosphorylation and
basal protein synthesis likely make it a
far better candidate therapy for SYN-
GAP1 haploinsufficiency. Importantly,
the selective effect on elevated protein
synthesis in Syngap/mice is similar to
that observed in Fmr1/y mice, suggest-
ing that dysregulation of mGlu5-ERK1/
2-dependent protein synthesis may be a
common feature of a subset of neurode-
velopmental disorders (Osterweil et al.,
2010, 2013; Tian et al., 2015). In sum-
mary, our findings suggest that target-
ing the exaggerated basal protein
synthesis through modulation of the
ERK1/2 pathway may provide a poten-
tial therapeutic strategy in the treatment
of SYNGAP haploinsufficiency.
Using STED microscopy, we reveal
nanoscale changes in spine morphology
in Syngap/ mice that indicate an in-
crease in biochemical compartmentaliza-
tion. These findings parallel those from
the Fmr1/y mice, where changes in spine
neck and head parameters decrease the
magnitude of the developmental change
in biochemical compartmentalization
that occurs in WT animals (Wijetunge et
al., 2014). As we suggested previously for
the Fmr1/ymice (Wijetunge et al., 2014),
we deem it unlikely that these subtle
changes in spine morphology can, by
themselves, fully account for the altera-
tions in synaptic function and plasticity.
Previous findings from SynGAP-
deficientmice suggest that changes in syn-
aptic function are mirrored by changes in
synaptic structure (Vazquez et al., 2004;
Carlisle et al., 2008; Clement et al., 2012;
but see McMahon et al. 2012). More spe-
cifically, SynGAP reduction resulted in an
increase in dendritic spine head size
(Vazquez et al., 2004; Carlisle et al., 2008;
Clement et al., 2012). Our finding of no change in spine head
width is at odds with those of Carlisle et al. (2008) andClement et
al. (2012), who examined hippocampal CA1 pyramidal neurons
and hippocampal dentate gyrus cells, respectively. Although
these differences may partly be due to differences in age and
neuronal type that were examined [for example, Carlisle et al.
(2008) examined animals up to 6 months of age, and we used
animals up to 5 weeks of age], it is likely that methodological
issues also explain some of the discrepancies. Both Clement et al.
(2012) and Carlisle et al. (2008) categorized spines into “mush-
room,” “thin,” and “stubby”; however, we demonstrated previ-
ously that spine shapes cover a wide continuum, and such
categories are arbitrary (Tønnesen et al., 2014; Wijetunge et al.,
2014). Carlisle et al. (2008) found small differences in the size of
Figure 6. CA1 pyramidal neuron dendritic spine morphology in Syngap/mice. A, Surface-rendered STED images of apical
dendritic segments from pyramidal neurons in the CA1 of the hippocampus of WT and Syngap/mice revealing morphological
details that are invisible to conventional lightmicroscopy. Scale bars, 500 nm.B–D, Kolmogorov–Smirnov tests of the cumulative
frequency distributions show that the distribution profiles of spine head widths (B) are not significantly different between geno-
types ( p 0.11), whereas distribution profiles of spine neck lengths and widths show that Syngap/mice (n 424 spines)
have significantly more spines with longer (C; p 0.005) and narrower necks (D; p 0.0008) compared to WT mice (n 393
spines). Themean values for these parameters are, however, not significantly different (WT, 523 14 nm, 246 10 nm, 114
4 nm, n 4; Syngap/, 536 11 nm, 276 19 nm, 106 1 nm, n 6, for head width, neck length, and neck width,
respectively). E, To predict the impact of these spinemorphology changes on diffusional coupling, a morphological compartmen-
talization factor was calculated. The cumulative frequency distributions of the compartmentalization factor significantly differ
between genotypes (Kolmogorov–Smirnov test, p 0.0001), and this is also reflected in the mean values for each genotype
(two-tailed independent t test with Welch’s correction, p 0.04; WT, 3.16 0.30m2; Syngap/, 4.35 0.37m2). n.s.,
Not significant; *p 0.05; **p 0.01.
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“mushroom” spines and no difference in “thin” or “stubby”
spines. However, without such categorization, it is unclear
whether the differences between genotype would have remained.
Clement et al. (2012) found only modest increases in head diam-
eter analyzed using cumulative distributions of spine head width.
They also found an increase in the relative proportion of “mush-
room” to “stubby” spines in Syngap/mice. However, the cat-
egorization of stubby spines may largely be a consequence of the
limited resolution of regular confocal and two-photon micros-
copy (200 and 350 nm, respectively) to resolve short spine
necks (Tønnesen et al., 2014). For these reasons, it is not appro-
priate to directly compare between these studies, and the appar-
ent differences may be simply due to differences in
methodological approach. Given the excellent resolution of the
STED microscope (70 nm) and the good agreement of our
findings of spine development with previous electron micro-
scopic studies (Harris et al., 1992), we argue that our measure-
ments are an accurate reflection of spine head morphology.
Previous studies in Fmr1/ymice have found a preponderance
of long thin spines and have correlated this with an increase in
LTD (for review, seeWijetunge et al., 2013).We propose that our
recent finding of an increase in spine head size (Wijetunge et al.,
2014) is more suggestive of spines that have recently undergone
potentiation and hence are pre-disposed to undergo LTD. Our
findings that Syngap/mice have no change in head size but do
show enhanced LTD indicate that these two parameters are not
functionally interdependent. Notwithstanding, both models
show an increase in biochemical compartmentalization, and fu-
ture studies will be required to determine whether compartmen-
talization and excess LTD are causally linked. Finally, it should be
noted that whereas an increase in head size in Fmr1/y mice was
generally thought to reflect a premature development of spines,
we demonstrated previously (also using STED microscopy) that
spine head size decreases with age in cortical layer 5 and hip-
pocampal CA1 pyramidal neurons inWTmice. This implies that
maintained large spine heads in Fmr1/y mice actually reflects a
developmental delay (Wijetunge et al., 2014).
In summary, our data demonstrate that two highly penetr-
ant forms of ID/ASDs resulting from mutations in FMR1 and
SYNGAP1 converge on common cellular processes. They are in
agreement with studies of the neurofibromatosis 1 (NF1) gene,
where mutations inNF1, encoding an RasGAP, also result in ID,
and some of its associated cellular and behavioral phenotypes are
alleviated by modulators of ERK1/2 signaling (Li et al., 2005).
Furthermore, they support the hypothesis that alterations in syn-
aptic plasticity resulting from dysregulation of new protein syn-
thesis may be a common core pathophysiology underlying these
disorders, and therapeutic strategies targeting modifiers of pro-
tein synthesis may be appropriate for treating genetically diver-
gent forms of ID/ASD.
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